Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

Autor: David W. Boulton, Hiddo J.L. Heerspink, Claire C J Dekkers, Valerie A. Cain, C. David Sjöström, Peter J. Greasley

Publikováno v: Diabetes, Obesity & Metabolism
Diabetes obesity & metabolism, 21(12), 2667-2673. Wiley

Aims To compare the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and to characterize the effects of dapagliflozin on ePV in a broad population of patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce4b4bf777abbea3357d175fcc14713
https://doi.org/10.1111/dom.13855

Correction of anemia by dapagliflozin in patients with type 2 diabetes

Autor: Bergur V. Stefánsson, Ricardo Correa-Rotter, David C. Wheeler, Peter J. Greasley, C. David Sjöström, Hiddo J.L. Heerspink, Valerie A. Cain, Peter Sartipy

Publikováno v: JOURNAL OF DIABETES AND ITS COMPLICATIONS, 34(12):107729. ELSEVIER SCIENCE INC

Aims: Anemia is common in type 2 diabetes (T2D), particularly in patients with kidney impairment, and often goes unrecognized. Dapagliflozin treatment increases hemoglobin and serum erythropoietin levels. We investigated the effect of dapagliflozin 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad98854fceddec9c3ce59a4cfb9a7c84
https://pubmed.ncbi.nlm.nih.gov/32948397

Author response for 'Effects of the SGLT2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes'

Autor: Claire C J Dekkers, David W. Boulton, Hiddo J.L. Heerspink, Valerie A. Cain, Peter J. Greasley, C. David Sjöström

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22cc24544a2e08bec59237a43f051323
https://doi.org/10.1111/dom.13855/v2/response1

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

Autor: Melissa Hallow, Bergur V. Stefánsson, Peter Sartipy, Peter Rossing, Valerie A. Cain, Silvio E. Inzucchi, Hiddo J.L. Heerspink, C. David Sjöström

Publikováno v: Diabetes obesity & metabolism, 21(3), 720-725. Wiley
Heerspink, H J L, Sjöström, C D, Inzucchi, S E, Hallow, M K, Cain, V A, Rossing, P, Stefansson, B V & Sartipy, P 2019, ' Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers ', Diabetes, Obesity and Metabolism, vol. 21, no. 3, pp. 720-725 . https://doi.org/10.1111/dom.13579
Diabetes, Obesity & Metabolism
Capital Region of Denmark

The sodium glucose co-transporter-2 inhibitor dapagliflozin has been shown to decrease urinary albumin-to-creatinine ratio (UACR). This effect, however, varies among individual patients. In this study, we assessed the baseline characteristics and con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e498317ddb43b8227979982c306822a2
https://research.rug.nl/en/publications/a9146c74-f24f-43f0-b2bc-0fa1bca2140d

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Autor: Valerie A. Cain, Paola Fioretto, C. David Sjöström, Bergur V. Stefánsson, Eva Johnsson

Publikováno v: Diabetologia

To the Editor: There is a growing body of evidence that sodium-glucose co-transporter 2 (SGLT2) inhibition may confer a renoprotective effect. This beneficial renal effect is thought to be achieved by mechanisms associated with reduced glucose and so

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dda8426141a0622ae3eeea123f649ea0
https://doi.org/10.1007/s00125-016-4017-1